Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome

Alberto Albanese, Alberto Esquenazi, Michael B. Chancellor, Elie Elovic, Karen R. Segal, David M. Simpson, Christopher P. Smith, Anthony B. Ward

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

80 Citazioni (Scopus)

Abstract

Botulinum neurotoxin (BoNT) can be injected to achieve therapeutic benefit across a large range of clinical conditions. To assess the efficacy and safety of BoNT injections for the treatment of spasticity associated with the upper motor neuron syndrome (UMNS), an expert panel reviewed evidence from the published literature. Data sources included English-language studies identified via MEDLINE, EMBASE, CINAHL, Current Contents, and the Cochrane Central Register of Controlled Trials. Evidence tables generated in the 2008 Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (AAN) review of the use of BoNT for autonomic disorders were also reviewed and updated. The panel evaluated evidence at several levels, supporting BoNT as a class, the serotypes BoNT-A and BoNT-B, as well as the four individual commercially available formulations: abobotulinumtoxinA (A/Abo), onabotulinumtoxinA (A/Ona), incobotulinumtoxinA (A/Inco), and rimabotulinumtoxinB (B/Rima). The panel ultimately made recommendations on the effectiveness of BoNT for the management of spasticity, based upon the strength of clinical evidence and following the AAN classification scale. While the prior report by the AAN provided recommendations for the use of BoNT as a class of drug, this report provides more detail and includes recommendations for the individual formulations. For the treatment of upper limb spasticity, the evidence supported a Level A recommendation for BoNT-A, A/Abo, and A/Ona, with a Level B recommendation for A/Inco; there was insufficient evidence to support a recommendation for B/Rima. For lower limb spasticity, there was sufficient clinical evidence to support a Level A recommendation for A/Ona individually and BoNT-A in aggregate; the clinical evidence for A/Abo supported a Level C recommendation; and there was insufficient information to recommend A/Inco and B/Rima (Level U). There is a need for further comparative effectiveness studies of the available BoNT formulations for the management of spasticity. © 2013 Elsevier Ltd.
Lingua originaleEnglish
pagine (da-a)115-128
Numero di pagine14
RivistaToxicon
Volume67
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • Adult spasticity
  • Evidence-Based Medicine
  • Evidenced-based review
  • Lower limp spasticity
  • Upper limb spasticity
  • Upper motor neuron syndrome
  • Botulinum Toxins, Type A
  • Humans
  • Injections, Intramuscular
  • Motor Neuron Disease
  • Muscle Spasticity
  • Neuromuscular Junction
  • Neurotoxins
  • Randomized Controlled Trials as Topic
  • Treatment Outcome
  • Botulinum neurotoxin

Fingerprint Entra nei temi di ricerca di 'Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome'. Insieme formano una fingerprint unica.

Cita questo